Considering that the cut-off used for defining hormone receptor positivity was not homogenous in all centers, the analyses comparing between patients with hormone receptor-positive and negative disease were then repeated by including only patients for whom the 1% cut-off for estrogen and/or progesterone receptor expression in their tumor was used to define hormone receptor status. This evidence concerns the gene PGR and neoplasm.